ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
74
MODERN METHODS OF PREVENTION AND TREATMENT OF STIS
Kamalov Azizbek Ruzalievich
Department of Internal Medicine No. 2, Assistant of Dermatovenereology, Central Asian
Medical University. Fergana, Uzbekistan
RELEVANCE
Sexually transmitted infections (STIs) represent a significant global public health challenge.
Each year, hundreds of millions of new STI cases occur worldwide, placing a heavy burden on
healthcare systems and societies. According to the World Health Organization (WHO), over 1
million curable STIs are acquired
every day
globally [1]. This translates to about 374 million
new infections annually with one of the four major curable STIs (chlamydia, gonorrhea, syphilis,
or trichomoniasis) in people aged 15–49 [1]. Additionally, viral STIs are widespread: for
example, over 38 million people are living with HIV/AIDS globally [2], an estimated 500
million people have genital herpes (HSV) [1], and human papillomavirus (HPV) causes around
311,000 cervical cancer deaths each year [1]. Beyond their prevalence, STIs carry serious
consequences — they can cause infertility, pregnancy complications, cancer, and increase the
risk of HIV acquisition [1]. STIs also impose social and economic costs: they contribute to
stigma, discrimination, and psychological distress, affecting individuals’ quality of life and
straining healthcare resources [3]. Despite being largely preventable and treatable, STIs remain a
global health priority due to rising infection rates in many regions and challenges such as
antimicrobial resistance. In fact, recent trends indicate resurgences of STIs in several countries
following disruptions in health services (e.g., during the COVID-19 pandemic) [4]. The global
importance of this topic is underscored by international calls for action and ambitious targets to
curb STI epidemics by 2030. Ensuring effective prevention and treatment of STIs worldwide is
crucial for improving sexual and reproductive health, achieving health equity, and reducing the
overall burden of disease.
Keywords:
Sexually transmitted infections (STIs); Prevention; Treatment; Vaccines; Public
Health; Antimicrobial Resistance; Global Health; HIV; HPV; Condom Use; Screening; Antiviral
Therapy
INTRODUCTION
STIs are infections primarily spread through sexual contact, caused by more than 30 different
bacteria, viruses, and parasites [1]. Common modes of transmission include vaginal, anal, and
oral sex; some STIs can also pass from mother to child during pregnancy or childbirth. Eight
pathogens account for the majority of STIs globally. Four of these are currently curable:
Chlamydia trachomatis
(chlamydia),
Neisseria gonorrhoeae
(gonorrhea),
Treponema pallidum
(syphilis), and
Trichomonas vaginalis
(trichomoniasis) [1]. The other four are viral infections
that are not curable with current therapies: HIV, HPV, herpes simplex virus (HSV), and hepatitis
B virus (HBV) [1].
STIs are among the most common communicable diseases worldwide, affecting people of all
genders and ages (particularly young adults).
Table 1
summarizes recent global incidence
estimates for the four main curable STIs. As shown, chlamydia and trichomoniasis are the most
frequently acquired, but all four infect millions of people each year [1]. These numbers highlight
the sheer scale of STI transmission. Furthermore, many infections are asymptomatic — the
ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
75
majority of individuals with a new STI may not have symptoms [1], which allows continued
spread if infections go undetected and untreated.
In addition to new cases each year, there is a large reservoir of chronic infections. For example,
an estimated 490 million people were living with genital HSV (herpes) in 2016 [1], and hundreds
of millions are persistently infected with high-risk HPV types or chronic hepatitis B. The high
prevalence and incidence of STIs underscore the need for effective prevention and treatment
strategies on a global scale.
STIs have far-reaching health impacts. Infection with one STI can increase susceptibility to
others — for instance, the presence of untreated syphilis, gonorrhea, or herpes can elevate the
risk of acquiring or transmitting HIV [1]. Untreated STIs can lead to serious complications:
syphilis infection in pregnancy can cause stillbirth or congenital syphilis in newborns, HPV can
cause cervical and other anogenital cancers, and gonorrhea or chlamydia can result in pelvic
inflammatory disease and infertility in women [1]. The importance of prevention and prompt
treatment is therefore paramount, not only to avert immediate symptoms but also to prevent
long-term sequelae and break the chain of transmission.
Over the past decades, the global health community has developed a range of interventions to
combat STIs — from condoms and educational programs to vaccines and novel medications.
This article will review modern methods of STI prevention and treatment, examining the most
effective strategies currently in use, recent innovations, and the evidence supporting them. A
global perspective is maintained, recognizing that STI control is a worldwide concern requiring
coordinated efforts and context-specific approaches.
Table 1.
Estimated global new infections of curable STIs (2020) [1]
STI (Pathogen)
New cases in 2020
Chlamydia (
C. trachomatis
)
~129 million
Gonorrhea (
N. gonorrhoeae
) ~82 million
Syphilis (
T. pallidum
)
~7.1 million
Trichomoniasis (
T. vaginalis
) ~156 million
Total (4 curable STIs)
~374 million
Materials and Methods
Study design:
This article is a narrative review and analysis of current STI prevention and
treatment methods, drawing on recent scientific literature and authoritative data sources. We
surveyed global health reports, guidelines, and research studies to identify modern, evidence-
based interventions against STIs.
Data sources:
Key epidemiological statistics were obtained from the World Health Organization
(WHO) fact sheets and global surveillance reports [1]. Additional data on intervention efficacy
and outcomes were gathered from peer-reviewed journals (including systematic reviews and
clinical trials) and official guidelines of agencies such as WHO and the U.S. Centers for Disease
Control and Prevention (CDC).
Literature search:
We performed targeted searches for terms such as “STI prevention,” “STI
treatment,” “HIV PrEP,” “HPV vaccine impact,” and “gonorrhea resistance” in databases and via
ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
76
organizational websites. Recent (2018–2024) publications were prioritized to ensure up-to-date
information.
Analysis approach:
We compared various prevention strategies (behavioral, barrier, biomedical,
and educational) and treatment modalities (antibiotics, antivirals, etc.), evaluating their
effectiveness and current role in global STI control. Special attention was given to innovations in
the past decade — for example, new vaccines, prophylactic therapies, and rapid diagnostic tools
— as well as ongoing challenges like antimicrobial resistance.
Frameworks:
The analysis was informed by global health strategies, including the WHO’s
Global Health Sector Strategy on STIs (2022–2030), which provided context on recommended
interventions and targets [5]. No new clinical data were collected for this article; instead, we
synthesized existing knowledge to provide a comprehensive overview.
Analysis and Results
Prevention Strategies
Modern prevention of STIs employs a combination of behavioral interventions, barrier methods,
prophylactic medications, and vaccines. No single method is 100% effective, so integrated
approaches are recommended, often termed “combination prevention.” Below, we detail the
most effective prevention strategies and summarize evidence of their impact.
Condom Use (Barrier Protection) -
Condoms remain a cornerstone of STI
prevention. When used consistently and correctly, condoms reduce the risk of HIV, gonorrhea,
chlamydia, trichomoniasis, and many other STIs [6]. They are widely available, inexpensive, and
also prevent unintended pregnancies, making them a dual-benefit intervention.
Sexual Health Education and Behavior Change -
Comprehensive sexual health
education programs aim to increase awareness of STIs and promote safer sexual behaviors. Such
programs, when culturally appropriate and consistently implemented, have been shown to
improve knowledge and reduce risky behaviors, thereby lowering STI rates [7]. Encouraging
open communication about sexual health and destigmatizing STIs are key behavioral aspects of
prevention.
Screening and Early Detection -
Regular screening for STIs is a preventive
strategy that identifies infections early so they can be treated before complications arise or
further transmission occurs. Many STIs are asymptomatic, so proactive testing is important,
especially for sexually active individuals with multiple partners or those in high-prevalence
settings. WHO’s latest guidance emphasizes expanding access to STI testing and diagnostics [4].
Partner Notification and Treatment -
Ensuring that the sexual partners of an
individual diagnosed with an STI are notified, tested, and treated is crucial in breaking the chain
of transmission. Some regions employ expedited partner therapy (EPT), where patients
diagnosed with certain STIs are given antibiotic prescriptions or medications for their partners.
Effective partner management is crucial for curable STIs.
Vaccination -
Vaccines are among the most powerful tools for preventing
infectious diseases. Two widely used STI vaccines are for HPV and hepatitis B. HPV
vaccination has significantly reduced HPV infections and related diseases in countries with high
vaccination coverage [8]. Hepatitis B vaccination has dramatically reduced new HBV infections.
Researchers are working on vaccines for other STIs, including herpes (HSV) and gonorrhea.
Pre-Exposure Prophylaxis (PrEP) for HIV -
One of the most significant
advancements in STI prevention is the advent of PrEP for HIV. Clinical trials showed high
efficacy in preventing HIV when taken consistently as prescribed [9]. PrEP is recommended for
ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
77
individuals at substantial risk of HIV infection. In addition to daily oral PrEP, newer options
include long-acting injectable PrEP, offering alternatives for those who struggle with pill
adherence.
Post-Exposure Prophylaxis (PEP) and Emerging Approaches -
Post-exposure
prophylaxis involves taking medications
after
a possible exposure, to prevent infection
(commonly used for HIV). Recent research shows that taking a single dose of the antibiotic
doxycycline after unprotected sex can prevent certain bacterial STIs (chlamydia, syphilis, and
partially gonorrhea) — a strategy called Doxy-PEP [10]. While promising, guidelines for
widespread Doxy-PEP use are under review due to concerns about antibiotic resistance.
Male Circumcision -
Voluntary medical male circumcision (VMMC) has been
adopted as an HIV prevention strategy in countries with high heterosexual transmission, after
clinical trials found that circumcision reduces the risk of male acquisition of HIV by about 60%
[11]. It also appears to lower rates of HPV and HSV-2.
Microbicides and Other Novel Prevention Technologies -
New forms of
prevention, such as the dapivirine vaginal ring, provide user-controlled options for women.
Large trials in Africa showed that the dapivirine ring can reduce the risk of HIV infection in
women by about 30–50% [12]. Other microbicide products are under research, and multipurpose
prevention technologies combining contraception with STI protection are in development.
Table 2.
Key STI Prevention Methods and Effectiveness
Prevention
Method
Description
Effectiveness/Impact
Condoms (Male &
Female)
Barrier devices used during sex
to block STI pathogens.
Highly effective (e.g., ~98% HIV risk
reduction) [6].
Sexual
Health
Education
Programs and counseling to
promote safe sex behaviors.
Increases condom use & testing,
lowers risky behaviors.
STI Screening &
Testing
Routine testing of at-risk
individuals.
Allows early detection & treatment;
prevents spread.
Partner Notification
& Treatment
Identifying and treating partners
of infected patients.
Reduces reinfection and community
transmission.
HPV Vaccination
Prevents HPV infection &
associated diseases.
~90% efficacy in preventing vaccine-
targeted HPV types.
Hepatitis
B
Vaccination
Prevents HBV infection.
~95% efficacy; crucial to global HBV
reduction.
HIV PrEP
Antiretroviral
drugs
taken
before exposure.
~99% effective for HIV prevention
when adherent [9].
PEP & Doxy-PEP
Medications after exposure to
prevent infection.
Effective for HIV (PEP). Doxy-PEP
reduces chlamydia & syphilis [10].
Male Circumcision
Surgical
removal
of
the
foreskin.
~60% reduction in female-to-male HIV
transmission [11].
Microbicides (e.g.,
Dapivirine)
Topical/intravaginal prevention
products.
30–50% HIV risk reduction in trials
[12].
Treatment Strategies
Effective treatment of STIs is as important as prevention, both for curing or managing infections
and for reducing infectiousness. Modern treatment approaches vary by the type of STI (bacterial
vs. viral).
ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
78
Bacterial STIs -
Curable with targeted antibiotics, though antibiotic resistance is a
growing concern, particularly with
Neisseria gonorrhoeae
. Recommended regimens include:
o
Chlamydia:
Azithromycin or doxycycline
o
Gonorrhea:
Dual therapy with ceftriaxone (injectable) plus doxycycline or
azithromycin (depending on guidelines) [13]
o
Syphilis:
Benzathine penicillin G (IM injection)
o
Trichomoniasis:
Metronidazole or tinidazole
Antibiotic resistance poses an urgent threat, especially for gonorrhea. WHO and CDC monitor
and update treatment guidelines to address resistance patterns [4].
Viral STIs -
Viral STIs cannot be eradicated with current therapies, but can be
effectively managed:
o
HIV:
Combination antiretroviral therapy (ART) suppresses viral replication, improves
immune function, and prevents transmission (U=U). Modern ART regimens are simpler and
more tolerable than in the past.
o
HSV:
Antiviral drugs (acyclovir, valacyclovir, famciclovir) reduce the frequency and
severity of outbreaks.
o
HPV:
No direct antiviral treatment; management focuses on removal of warts and
precancerous lesions. HPV vaccination is the key preventive measure.
o
Hepatitis B:
Long-term antivirals (tenofovir, entecavir) can suppress replication and
prevent liver damage; not usually curative but highly effective.
o
Hepatitis C:
Direct-acting antivirals can cure most HCV infections in 8–12 weeks,
though reinfection can occur.
Challenges in Treatment — Antimicrobial Resistance (AMR) -
AMR is a major
concern for STI management, especially in gonorrhea. Cases of extensively drug-resistant
gonorrhea have been reported in multiple regions [14]. New antibiotics and alternative therapies
(e.g., potential gonococcal vaccines) are being researched [15]. Antibiotic stewardship and
global surveillance are crucial.
Innovations in Treatment Delivery -
Strategies like rapid treatment initiation,
syndromic management, telemedicine, and point-of-care testing help ensure prompt care. Same-
day antibiotic treatment can curb transmission. Long-acting injectable ART for HIV and new
methods for HCV treatment have transformed the landscape of chronic viral STIs, improving
adherence and health outcomes [16].
Conclusion and Recommendations Summary:
STIs remain a major global health concern, but modern prevention (condoms, education,
screening, partner services, vaccination, PrEP, male circumcision, microbicides) and treatment
(antibiotics, antivirals) strategies provide powerful means to reduce their impact. Challenges like
antibiotic resistance, healthcare access gaps, and social stigma persist. Addressing these requires
sustained efforts, investment, and research.
Global Perspective and Future Directions:
1.
Scale Up Proven Interventions:
Ensure widespread availability of condoms, testing,
education, and vaccines (HPV, hepatitis B) to achieve high coverage, particularly in under-
resourced settings.
2.
Strengthen Health Systems and Access:
Invest in healthcare infrastructure to guarantee
essential drugs (e.g., benzathine penicillin) and diagnostic tools are consistently available.
ILMIY TADQIQOTLAR VA ULARNING YECHIMLARI JURNALI
JOURNAL OF SCIENTIFIC RESEARCH AND THEIR SOLUTIONS
VOLUME 3, ISSUE 02, FEVRAL 2025
WORLDLY KNOWLEDGE NASHRIYOTI
worldlyjournals.com
79
3.
Enhance Surveillance and Response:
Improve global surveillance to detect STI trends
and emerging resistance.
4.
Combat Antimicrobial Resistance:
Develop new antibiotics and vaccines; use existing
therapies judiciously; carefully monitor strategies like Doxy-PEP to avoid accelerating resistance.
5.
Innovate and Research:
Continue supporting research into rapid, affordable diagnostics,
new therapies (especially for gonorrhea), and vaccines for unmet needs (HIV, HSV, gonorrhea,
chlamydia).
6.
Global Collaboration and Education:
Share resources and best practices across borders;
involve communities to combat stigma and improve uptake of STI services.
By applying a combination of proven and innovative strategies, the global community can move
toward significantly reducing the burden of STIs, mitigating antibiotic resistance, and achieving
international targets for sexual and reproductive health.
References
1.
World Health Organization (WHO).
Sexually transmitted infections (STIs) Fact Sheet.
WHO Newsroom, 21 May 2024.
2.
Afolayan EF, et al.
Global perspectives on the burden of sexually transmitted diseases: A
narrative review.
Medicine (Baltimore). 2024;103(26):e13991.
3.
Global Forum on STI Stigma.
Socioeconomic impacts of sexually transmitted infections.
Published online 2023.
4.
WHO News Release.
WHO releases new guidance to improve testing and diagnosis of
STIs.
24 July 2023.
5.
WHO.
Global Health Sector Strategy on STIs 2022–2030.
Geneva: WHO; 2022.
6.
CIDRAP News.
1 million new STIs diagnosed each day.
University of Minnesota, 06
June 2019.
7.
Wei C, et al.
Advances and challenges in STI prevention among MSM in Asia.
Curr Opin
Infect Dis. 2023;36(2):61-69.
8.
CDC.
HPV Vaccine Effectiveness.
U.S. Centers for Disease Control and Prevention,
updated 2021.
9.
HIV.gov.
Pre-Exposure Prophylaxis (PrEP).
Updated 2025.
10.
Johns Hopkins Bloomberg School of Public Health.
DoxyPEP: A “Morning-After Pill”
for STIs.
Interview with Dr. Matthew Hamill, Dec 18, 2023.
11.
WHO, UNAIDS.
Voluntary Medical Male Circumcision for HIV Prevention.
2023 update.
12.
WHO.
Dapivirine vaginal ring: a new HIV prevention option for women.
2021.
13.
CDC.
Drug-Resistant Gonorrhea.
CDC Fact Sheet, Feb 2024.
14.
Akiljanovna, Mukhammadjonova Liliya. "THE COURSE OF PSORIASIS IN YOUNG
AND OLDER CHILDREN." Ethiopian International Journal of Multidisciplinary Research 11,
no. 03 (2024): 205-207.
15.
Bahadyrovna, Nasritdinova Nargiz, and Mukhammadjonova Liliya Akiljanovna.
"FEATURES OF THE COURSE OF ATOPIC DERMATITIS." Ethiopian International Journal
of Multidisciplinary Research 11, no. 03 (2024): 208-209.
16.
Akiljanovna, M.L. and Bahadyrovna, N.N., 2023. THE ORIGIN
OF
NUMMULARDERMATITIS, THE MOST EFFECTIVE METHODS OF TREATMENT.
International Multidisciplinary Journal for Research & Development, 10(10).
